Symphogen has raised a total of €75 million to date in equity capital through an international investor syndicate including Essex Woodlands Health Ventures (USA), Scandinavian Life Science Ventures (S/DK), Novo A/S (DK), LD Pensions (DK), Danske Bank (DK), Sunstone Capital (DK), Gilde Healthcare Partners (Netherlands), Tri-Takeda (Japan) and Genentech (USA).

Symphogen Investors:
Essex Woodlands Health Ventures
Scandinavian Life Science Ventures
Novo A/S
LD Pensions
Danske Bank
Sunstone Capital
Gilde Healthcare Partners
Tri-Takeda